CliffBio
small molecule

ACYCLOVIR

ACYCLOVIR

Loss of exclusivity—loss of exclusivity
CompanyAlembic →See this company's full patent-cliff portfolio

Drug detail

Brand nameACYCLOVIR
Active ingredientACYCLOVIR
Strength5%
Dosage formCREAM
RouteTOPICAL
ModalitySmall molecule
FDA approvalNovember 2023
Marketing statusRX

More from Alembic

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.